Swedish pharmaceutical company Xspray Pharma (STO:XSPRAY) announced on Friday the launch of new bioequivalence studies with a slightly modified formulation of HyNap-Dasa.
Xspray Pharma's leading product candidates, HyNap-Dasa and HyNap-Nilo, are stable amorphous versions of the blockbuster cancer drugs Sprycel (dasatinib) and Tasigna (nilotinib). HyNap-Dasa is being developed in two versions, a generic and an improved version. HyNap-Nilo is being developed as an improved version and has received orphan drug status from the US Food and Drug Administration (FDA).
The new studies are being conducted on healthy volunteers with the objective to demonstrate that HyNap-Dasa is bioequivalent to Sprycel, in order for the company to be able to submit an abbreviated new drug application (ANDA) in the United States. Preliminary results are expected at the beginning of the second quarter.
The first study involves fasted healthy volunteers, while the second study, due to start in early February, will involve non-fasted healthy volunteers.
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical